Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.2241
-0.0059 (-2.57%)
Mar 13, 2026, 2:32 PM EST
Northwest Biotherapeutics Employees
Northwest Biotherapeutics had 25 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
25
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$37,480
Profits / Employee
-$3,648,960
Market Cap
360.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 25 | 0 | - | 25 | 0 |
| Dec 31, 2023 | 25 | 3 | 13.64% | 25 | 0 |
| Dec 31, 2022 | 22 | 3 | 15.79% | 22 | 0 |
| Dec 31, 2021 | 19 | 0 | - | 19 | 0 |
| Dec 31, 2020 | 19 | 2 | 11.76% | 19 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vaxart | 105 |
| Silence Therapeutics | 88 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| Harvard Apparatus Regenerative Technology | 8 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Northwest Biotherapeutics News
- 4 months ago - Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility - PRNewsWire
- 5 months ago - Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed - PRNewsWire
- 7 months ago - Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd. - PRNewsWire
- 7 months ago - Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman - PRNewsWire
- 9 months ago - Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property - PRNewsWire